September 2022

BMS supports patient preference study – continuing research investment for the beta-thalassemia community

HCD Economics has championed the application of Time Trade Off (TTO) methodology, to the research objective of expanding the health economic evidence for treatments that improve the life of patients. A number of TTO studies are underway and in the March 22nd edition of the prestigious European Journal of Health Economics (impact factor 3.689 [2020] - 472,118 downloads (2021), the TTO study undertaken by HCD Economics was published and is available now as an open access publication. (https://link.springer.com/article/10.1007/s10198-022-01449-7).
Read More
July 2022

A Real World Leader for every patient in Europe

The European Medicines Agency (EMA), which serves a population of 500 million citizens, has the stated remit of promoting and protecting public health in European Union (EU) member states, as well as the countries in the European Economic Area, by ensuring all medicines available on the EU market are safe, effective and of high quality.
Read More
May 2022

ISPOR 2022 – in Washington DC and in-person!

The HCD and Prime Access team attended ISPOR (The International Society for Pharmaeconomics and Outcomes Research) ‘in-person’, the first time since the COVID-19 pandemic that the conference returned to an in-person event (with on-line participation still available for those delegates preferring to participate virtually).
Read More
May 2022

360,000 compelling reasons to invest in patient empowered Fabry Disease research

Although around 4-5000 people are known to be diagnosed with Fabry Disease in the United States (Mol Genet Metab 2008, 93:112-128), the US National Fabry Foundation proposes that just under 30,000 US citizens could be living, unknowingly, with classic and non-classic Fabry disease (https://www.fabrydisease.org/index.php/about-fabry-disease/how-many-people-have-fabry-disease
Read More
April 2022

HCD Economics continues to expand socio-economic understanding of Movement Disorders.

Movement disorders are commonly neurological, involving both voluntary and involuntary abnormal, reduced or slowed movement. Ataxia affects the cerebellum, the brain’s coordination centre, causing uncoordinated, clumsy balance and limb movements as well as impaired speech. Dystonia involves sustained involuntary muscle contractions with twisting, repetitive movements. Myoclonus muscle jerks can be lightning-quick, effecting either a single muscle or a whole group of muscles. Chorea is characterized by repetitive, brief, irregular rapid, involuntary movements commonly of the face, mouth, trunk and limbs. HCD Economics has already conducted a large Burden of Illness Study of Huntington’s Chorea, one of the most well know genetic diseases.
Read More